4.4 Article

Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme-Study design and current status report

Journal

APPLIED RADIATION AND ISOTOPES
Volume 69, Issue 12, Pages 1796-1799

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.apradiso.2011.03.014

Keywords

Boron neutron capture therapy; Fractionated X-ray irradiation; Glioblastoma; Temozolomide; Phase II clinical study

Funding

  1. Ministry of Health, Labor and Welfare of Japan
  2. Japanese Ministry of Education, Science, and Culture [21890283, 20591728, 22791361]
  3. Takeda Science Foundation
  4. Grants-in-Aid for Scientific Research [21890283, 22791361, 20591728, 23390355, 23659596, 23592146] Funding Source: KAKEN

Ask authors/readers for more resources

Recently, we reported our clinical experiences of boron neutron capture therapy (BNCT) for the newly diagnosed glioblastoma. The major differences of our protocol from the other past studies were simultaneous use of both sodium borocapate and boronophenylalanine, and combination with fractionated X-ray irradiation. These results showed the efficacy of combination therapy with external beam X-ray irradiation and BNCT. For our future study, we planned the multi-centric phase II clinical study for newly diagnosed glioblastoma patients in Japan (OSAKA-TRIBRAIN0902, NCT00974987). (C) 2011 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available